On April 6, 2026 Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, reported that the company will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, CA, from April 17 – 22, 2026. The presentations demonstrate Biodesix capabilities in blood- and tissue-based testing and monitoring across a range of applications.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Biodesix expertise in test discovery and development, regulatory, reimbursement, and commercialization provides an exceptional level of service for our partners across a range of applications. The AACR (Free AACR Whitepaper) presentations showcase basic research through clinical applications and pre-validated assays available for biopharma and life science partners, as well as advancements in our pipeline efforts. The data are reinforced by more than a decade of experience supporting the clinical development and commercialization of new diagnostics and therapeutics," said Gary Pestano, PhD, Chief Scientific Officer, Biodesix.
"The depth of experience and success across the Biodesix team, spanning real-world clinical care and cutting-edge research, will be on full display at this year’s AACR (Free AACR Whitepaper). It is especially exciting to see our genomic and proteomic technologies, combined with advanced data informatics, translating into meaningful clinical impact in our pipeline product concepts while also fueling strong momentum in our Development Services business as we move into 2026," said Scott Hutton, CEO, Biodesix.
Tumor & Immune Profiling Expertise
Biodesix oral and poster presentations highlight diverse technology platforms, rapid turn-around times for our clinical tests, and extensive capabilities in immune and tumor profiling using mass spectrometry, Bio-Rad Droplet Digital PCR, and Thermo Fisher Ion AmpliSeq platforms. In addition, Biodesix has validated a new clinical myeloid panel on the Thermo Fisher Ion Torrent Genexus System. The platform supports an automated clinical next-generation sequencing (NGS) workflow and can deliver sequencing results in as little as 24 hours.
Sunday, April 19 | 3PM–5PM PST | Oral Presentation | Room 17, Mezzanine Level, Convention Center
Title: Real-world analysis of NSCLC* variant-level frequencies from liquid biopsy testing in diverse U.S. populations
Monday, April 20 | 2PM–5PM PST | Poster Section 41
Poster: 3743. ddPLEX EGFR/KRAS/BRAF: A highly multiplexed droplet digital PCR (ddPCR) panel for ultra-sensitive NSCLC biomarker detection
Wednesday, April 22 | 9AM–12PM PST | Poster Section 39
Poster: Blood-based proteomic profiling reveals novel biomarkers of Neuroendocrine Prostate Cancer
Monday, April 20 | 2PM–5PM PST | Poster Section 44
Title: Performance validation of a next generation sequencing myeloid assay on an integrated nucleic acid purification and sequencing system
Molecular Residual Disease (MRD) Product Pipeline
Another set of presentations highlights a novel, multi-omic approach to MRD monitoring. Thermo Fisher Scientific, Bio-Rad Laboratories, and Memorial Sloan Kettering Cancer Center will co-present new data on proteomic and genomic biomarkers as well as bioinformatics workflows central to the Biodesix MRD pipeline tests.
Monday, April 20 | 12:30PM | Spotlight Theater B – Sails Pavilion – Conv Ctr
Title: Leveraging Droplet Digital PCR* (ddPCR) for MRD Detection and Monitoring in Solid Tumors and Heme Malignancies
Tuesday, April 21 | 2PM–5PM PST | Poster Section 1
Poster: 5437. Sensitive detection of rare cfDNA variants utilizing molecular technologies and a novel informatics platform: A combined genomic and proteomic MRD application.
Wednesday, April 22 | 9AM–12PM PST | Poster Section 45
Poster: 7828. Development of a comprehensive tumor-informed ctDNA workflow for ultrasensitive molecular residual disease (MRD) detection using diverse tumor profiling inputs
The full abstracts for Biodesix and a list of all abstracts being presented at the AACR (Free AACR Whitepaper) Annual Meeting can be found here.
ddPCR technology is a trademark of Bio-Rad Laboratories, Inc.
Ion Torrent Genexus System and Ion AmpliSeq Platform are trademarks of Thermo Fisher Scientific.
NSCLC is the acronym for Non-Small Cell Lung Cancer.
(Press release, Biodesix, APR 6, 2026, View Source [SID1234664192])